1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 22 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Glucagon-like peptides 1 and 2 in health and disease: A reviewMarathe, C.; Rayner, C.; Jones, K.; Horowitz, M.
2007Effects of protein on glycemic and incretin responses and gastric emptying after oral glucose in healthy subjectsKaramanlis, A.; Chaikomin, R.; Doran, S.; Bellon, M.; Bartholomeusz, D.; Wishart, J.; Jones, K.; Horowitz, M.; Rayner, C.
2014Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjectsPlummer, M.; Jones, K.; Annink, C.; Cousins, C.; Meier, J.; Chapman, M.; Horowitz, M.; Deane, A.
2014Incretins and the intensivist: what are they and what does an intensivist need to know about them?Plummer, M.; Chapman, M.; Horowitz, M.; Deane, A.
2014Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metforminWu, T.; Ma, J.; Bound, M.; Checklin, H.; Deacon, C.; Jones, K.; Horowitz, M.; Rayner, C.
2019Comparative effects of proximal and distal small intestinal glucose exposure on glycemia, incretin hormone secretion, and the incretin effect in health and type 2 diabetesZhang, X.; Young, R.L.; Bound, M.; Hu, S.; Jones, K.L.; Horowitz, M.; Rayner, C.K.; Wu, T.
2016A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetesWu, T.; Little, T.; Bound, M.; Borg, M.; Zhang, X.; Deacon, C.; Horowitz, M.; Jones, K.; Rayner, C.
2013Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetesChang, J.; Wu, T.; Greenfield, J.; Samocha-Bonet, D.; Horowitz, M.; Rayner, C.
2014Protein 'pre-loads' in type 2 diabetes: what do we know and what do we need to find out?Rayner, C.K.; Ma, J.; Jones, K.L.; Clifton, P.M.; Horowitz, M.
2008Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutideHorowitz, M.; Visboll, T.; Zdravkovic, M.; Hammer, M.; Madsbad, S.

Discover